Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ATF1 | P18846 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30809049 | 1.00 | HRH4 (0.35) | HRH4ATF1NFKB1CYP1A2PDE4A | |
| SCHEMBL26685429 | 0.89 | HRH4 (0.36) | HRH4ATF1NFKB1CYP1A2PDE4A | |
| SCHEMBL30632784 | 0.89 | HRH4 (0.36) | HRH4ATF1NFKB1CYP1A2PDE4A | |
| SCHEMBL628056 | 0.82 | NT5E (0.39) | ATF1NFKB1CYP2C19 | |
| SCHEMBL2721824 | 0.82 | HRH4 (0.49) | HRH4LMNASMN1; SMN2 | |
| SCHEMBL29438115 | 0.82 | HRH4 (0.49) | HRH4LMNASMN1; SMN2 | |
| SCHEMBL31543344 | 0.81 | ALDH1A1 (0.36) | — | |
| SCHEMBL27029966 | 0.81 | KMT2A (0.44) | HRH4CYP1A2PDE4ACYP2C19LMNA | |
| SCHEMBL10555728 | 0.80 | ATF1 (0.33) | ATF1NFKB1 | |
| SCHEMBL10558546 | 0.80 | ATF1 (0.33) | ATF1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2023250064-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11634410-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634410-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210309644-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309644-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10988463-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | PFIZER INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988463-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | PFIZER INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3397631-B1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3397631-B1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER (US) | 2021-04-07 | — | — | EP | disclosed |
| US-9809579-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | PFIZER INC. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017115205-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170183328-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183328-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183328-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | PFIZER INC. | 2017-06-29 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309644-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | HK1, GCK, KHK | HRH4 3688/4885ATF1 1468/4885NFKB1 842/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | HRH4 2502/4885ATF1 4787/4885NFKB1 1349/4885 |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | HRH4 3371/4885ATF1 2168/4885NFKB1 834/4885 |
| US-11634410-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | HK1, GCK, KHK | HRH4 3688/4885ATF1 1468/4885NFKB1 842/4885 |
| US-10988463-B2 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | HK1, GCK, KHK | HRH4 3688/4885ATF1 1468/4885NFKB1 842/4885 |
| US-20170183328-A1 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | HK1, GCK, KHK | HRH4 3688/4885ATF1 1468/4885NFKB1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.